The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor.

Ann Rheum Dis · 2015 · PMC4316858 · PMID 24297378

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

borderline significanceno p-value reported

At 12 months, response rates based on change in CDAI seemed to favour anti-TNF users with borderline significance (difference in mean change of CDAI of −1.64; 95% CI −3.47 to 0.19).

also in 7,017 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.